Announced Date: 2025-12-09 (December 9, 2025)
Licensor (Seller): Chongqing Yao Pharmaceutical, Subsidiary of Fosun Pharma (China)
Licensee (Buyer): Pfizer
.
Asset Name: YP05002
Asset Modality: Small Molecule
Asset Target: glucagon-like peptide-1 receptor (GLP-1R) agonists
Potential Indication: chronic weight management, type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), among others.
Currently Stage: Phase 1 clinical development in Australia
.
Scope of Authority:
Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license covers all indications for therapeutic, diagnostic, and prophylactic human and veterinary use.
.
Under the terms of the agreement, Yao Pharma will complete an ongoing YP05002 Phase 1 clinical trial in Australia and grants Pfizer an exclusive license to further develop, manufacture and commercialize YP05002 worldwide.
.
Payment Detail:
Yao Pharma will receive
Upfront payment of $150 million,
Eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $1.935 billion,
Tiered royalties on sales, if approved.
.
Link:
Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma | Pfizer
.
.
Note:
Chinese Name
Chongqing Yao Pharmaceutical 重庆药友制药
Fosun Pharma 复星医药
